INVO Bioscience Announces Birth From INVOcell

INVO Bioscience (OTC:IVOB) announced the birth of the first two babies conceived through the INVOcell technology.
As quoted in the press release:

Marin Fertility Center has been offering the INVOcell and INVO procedure since late 2016, when the twins were conceived. Dr. Peter Uzelac, a reproductive endocrinologist said, “This technology simplifies the IVF process, driving down the cost to make it more accessible to patients that would not otherwise be able to afford care.”
The mother of the twins, a 30-year-old woman, had tubal factor infertility and had been trying for two years to conceive. Dr. Jennifer Agard, a reproductive endocrinologist with Marin Fertility Center since 2015, was the lead doctor treating the patient looking for a more cost-effective alternative to traditional IVF.
“INVO Bioscience is delighted to have Marin Fertility Center furthering our mission in California to provide affordable, safe and effective treatment for infertility,” said Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience. “Drs. Uzelac and Agard, along with the team at Marin Fertility Center, were early adopters of the INVOcell Intravaginal Culture System, and we share in the joy of family building for these deserving patients.”

Click here to read the full press release. 

Source: www.accesswire.com